PERCE-MUCO: Perceptions and Expectations of People With Cystic Fibrosis Regarding a Change in Treatment

Condition(s) studied

Study summary

PERCE-MUCO is a prospective, multicentre, mixed-methods observational study investigating the perceptions, expectations and treatment-change intentions of adults with cystic fibrosis who are currently treated with elexacaftor/tezacaftor/ivacaftor (ETI) or whose treatment has been medically discontinued. The study focuses on patients' stated willingness to switch from ETI to vanzacaftor/tezacaftor/deutivacaftor (VTD), and on the factors associated with this intention, including treatment satisfaction, knowledge and expectations regarding VTD, quality of life, treatment adherence, reported adverse effects, access-related concerns and desired support from an advanced practice nurse. The quantitative component uses a study-specific questionnaire and routine-care CFQ-R 14+ and Morisky-8 data. A qualitative component consists of semi-structured interviews at the Roscoff cystic fibrosis centre.

Eligibility

Primary outcome measure(s)

• Intention to switch from ETI to VTD — At completion of the PERCE-MUCO questionnaire at inclusion (single assessment).
  Percentage of participants selecting each of three responses to the question: 'If your physician offered VTD tomorrow, what would your position be?' Response options: immediate acceptance; need time to think; refusal. Report proportions and 95% confidence intervals

Trial sites (11)

More Fondation Ildys trials in France

Other trials for the same condition